Trial Outcomes & Findings for Institutional Audit of the Use of Intravenous Acetaminophen in Infants Undergoing Pyloromyotomy (NCT NCT02359305)

NCT ID: NCT02359305

Last Updated: 2018-02-05

Results Overview

One time in the OR prior to the start of surgery

Recruitment status

COMPLETED

Target enrollment

68 participants

Primary outcome timeframe

Baseline

Results posted on

2018-02-05

Participant Flow

Participant milestones

Participant milestones
Measure
IV Acetaminophen
Acetaminophen given by intravenous infusion.
Rectal Acetaminophen
Acetaminophen given by rectal suppository.
Overall Study
STARTED
34
34
Overall Study
COMPLETED
34
34
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Institutional Audit of the Use of Intravenous Acetaminophen in Infants Undergoing Pyloromyotomy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
IV Acetaminophen
n=34 Participants
Acetaminophen administered by intravenous infusion.
Rectal Acetaminophen
n=34 Participants
Acetaminophen administered by rectal suppository.
Total
n=68 Participants
Total of all reporting groups
Age, Categorical
<=18 years
34 Participants
n=5 Participants
34 Participants
n=7 Participants
68 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
34.2 days
STANDARD_DEVIATION 14.5 • n=5 Participants
37.8 days
STANDARD_DEVIATION 16.5 • n=7 Participants
36 days
STANDARD_DEVIATION 15.5 • n=5 Participants
Sex: Female, Male
Female
5 Participants
n=5 Participants
5 Participants
n=7 Participants
10 Participants
n=5 Participants
Sex: Female, Male
Male
29 Participants
n=5 Participants
29 Participants
n=7 Participants
58 Participants
n=5 Participants
Region of Enrollment
United States
34 participants
n=5 Participants
34 participants
n=7 Participants
68 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline

One time in the OR prior to the start of surgery

Outcome measures

Outcome measures
Measure
IV Acetaminophen
n=34 Participants
Acetaminophen administered by intravenous infusion.
Rectal Acetaminophen
n=34 Participants
Acetaminophen administered by rectal suppository.
Acetaminophen Dosage
8.6 mg/kg
Standard Deviation 3.9
30.7 mg/kg
Standard Deviation 6.3

PRIMARY outcome

Timeframe: 0-60 minutes post-operatively

The Face, Legs, Activity, Cry, Consolability scale or FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain.

Outcome measures

Outcome measures
Measure
IV Acetaminophen
n=34 Participants
Acetaminophen administered by intravenous infusion.
Rectal Acetaminophen
n=34 Participants
Acetaminophen administered by rectal suppository.
Average FLACC Pain Score in the PACU
0.3 units on a scale 0-10
Standard Deviation 0.6
0.6 units on a scale 0-10
Standard Deviation 1

SECONDARY outcome

Timeframe: 45-60 minutes post-operatively

Time spent in the post-anesthesia care unit post-operatively.

Outcome measures

Outcome measures
Measure
IV Acetaminophen
n=34 Participants
Acetaminophen administered by intravenous infusion.
Rectal Acetaminophen
n=34 Participants
Acetaminophen administered by rectal suppository.
PACU Time
48 minutes
Standard Deviation 19.9
50.4 minutes
Standard Deviation 12

Adverse Events

IV Acetaminophen

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Rectal Acetaminophen

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Arlyne Thung

Nationwide Children's Hospital - Dept. of Anesthesiology & Pain Medicine

Phone: 614-722-4200

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place